| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09:10 | Evotec-Aktie: Das könnte für einen weiteren Kursanstieg sprechen | 914 | sharedeals.de | Am Mittwoch war die Erleichterung über die Waffenruhe im Iran-Konflikt deutlich zu spüren. Hohe Kursanstiege waren zu verzeichnen. Das Biotech-Unternehmen Evotec konnte ebenfalls deutlich zulegen. Am... ► Artikel lesen | |
| 09:15 | Mutares: Exklusiv-Interview - Deutz, Elmos, Evotec, Infineon und Rheinmetall - Börse Frankfurt | 817 | 4investors | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| Mi | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists | 775 | PR Newswire | WASHINGTON, April 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of Thetis, a clinical trial evaluating... ► Artikel lesen | |
| 14:33 | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | 521 | EQS Group (DE) | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen | |
| 07:10 | Idorsia Pharmaceuticals Ltd: Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development | 456 | GlobeNewswire (Europe) | Idorsia thanks Alberto Gimona - most recently Head of Global Clinical Development and Medical Affairs - and wishes him all the best for a well-deserved retirementAmer Joseph joins Idorsia as EVP, Chief... ► Artikel lesen | |
| 07:22 | Basilea Pharmaceutica International Ltd, Allschwil: Basilea erhält zusätzliche USD 6 Mio. von CARB-X für die klinische Entwicklung des Antibiotikums BAL2420 | 439 | GlobeNewswire (Deutschland) | Zusage der finanziellen Förderung nach erfolgreichem Abschluss präklinischer Studien und Erhalt der Genehmigung zur Durchführung klinischer Studien Zusätzliche USD 6 Mio. für die erstmalige Erprobung... ► Artikel lesen | |
| 00:01 | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | 327 | Business Wire | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| Mi | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.04.2026 | 326 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 08.04.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.04.2026ISIN NameCA09173B1076 BITFARMS... ► Artikel lesen | |
| Mi | Marvel Biosciences Corp.: Marvel Biosciences Announces Proposed Convertible Debenture Offering | 321 | Newsfile | Calgary, Alberta--(Newsfile Corp. - April 8, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Company") announced today its intention to complete a non-brokered private placement... ► Artikel lesen | |
| 07:00 | FDA-Fortschritt bei Zelltherapien: Mesoblast startet entscheidende Studie in Duchenne - neuer Kurstreiber? | Small- & Micro Cap Investment | |||
| 12:06 | Zymeworks Inc.: Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth | 268 | GlobeNewswire (Europe) | • Adam Schayowitz, Ph.D., MBA appointed as Head of R&D• Scott Platshon appointed as Chief Business Officer VANCOUVER, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq:... ► Artikel lesen | |
| 07:22 | Basilea Pharmaceutica International Ltd, Allschwil: Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420 | 246 | GlobeNewswire (Europe) | Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor) first-in-human... ► Artikel lesen | |
| 13:02 | Zeo ScientifiX, Inc.: Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics - Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX | 245 | ACCESS Newswire | Regen Therapy's 24,000-practitioner network will unlock a fully integrated care ecosystem - featuring Stealth Health's licensed prescriber team and specialized therapies, Metabolic Code-driven longevity... ► Artikel lesen | |
| 14:12 | C4 Therapeutics Enters Collaboration Agreement With Roche | 242 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - C4 Therapeutics (CCCC) has entered into a new collaboration agreement with Roche (RHHBY, RO.SW, ROG.SW) to advance research in the degrader-antibody conjugate... ► Artikel lesen | |
| 15:36 | Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline | 238 | AFX News | FOSTER CITY (dpa-AFX) - Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to build and advance its... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| BB BIOTECH | 48,450 | 2,47 | +5,10 % | 2,25 | 23.03.2026 | |
| CSL | 85,20 | 2,61 | +3,06 % | 1,84 | 10.03.2026 | |
| AMGEN | 305,40 | 8,36 | +2,74 % | 2,52 | 15.05.2026 | |
| RECORDATI | 49,200 | 1,30 | +2,64 % | 0,71 | 18.05.2026 | |
| NOVONESIS | 51,08 | 0,87 | +1,70 % | 4,25 | 20.03.2026 | |
| SINO BIOPHARM | 0,643 | 0,01 | +1,56 % | 0,05 | 24.06.2026 | |
| GENUS | 29,800 | 0,38 | +1,28 % | 0,11 | 05.03.2026 | |
| VITROLIFE | 8,735 | 0,10 | +1,14 % | 1,10 | 06.05.2026 | |
| 3SBIO | 2,760 | 0,03 | +1,09 % | 0,25 | 21.07.2026 | |
| BIOMERIEUX | 89,55 | 0,90 | +1,01 % | 0,98 | 09.06.2026 |